Abstract: The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a suitable expression system, and wherein at least one step is provided that results in a reduced acetylation rate of sialic acid residues in the glycoprotein (FIG. 16).

Abstract: The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to a method or process of producing a glycoprotein that interacts with, or acts as an agonist to, the erythropoietin receptor (EpoR), which glycoprotein has modified efficacy, wherein the method or process comprises the heterologous expression of said glycoprotein in a suitable expression system, and wherein at least one step is provided that results in a reduced acetylation rate of sialic acid residues in the glycoprotein (FIG. 16).

Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occurring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.

Abstract: The present invention relates to the identification, the isolation and the use of molecules interfering with the function (s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful for identifying and isolating molecules, which have the capacity to modulate PVR mediated adhesion or invasion potential of cells.

Abstract: The present invention relates to the identification, the isolation and the use of molecules interfering with the function(s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful for identifying and isolating molecules which have the capacity to modulate PVR mediated adhesion or invasion potential of cells.

Abstract: The present invention relates to molecules interfering with the function of neuropilin-1 in the context of angiogenesis and the treatment of cancer. Molecules, polypeptides, antibodies, compositions and methods are provided that are useful for reducing, inhibiting or treating angiogenesis, the invasion of blood vessels into tumors, and/or the invasion or the metastatic potential of specific tumor cells. Additionally, a method is provided that allows identifying molecules, which interfere with the functionality of neuropilin-1. Furthermore, a method is provided that allows determining whether a naturally occuring tumor cell depends on functional neuropilin-1 for its invasiveness and/or metastatic potential.